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Abstract We studied the correlation between epidermal
growth factor receptor (EGFR) and the tumor stem cell
markers CD44/CD24 in breast invasive ductal carcinoma
(BIDC) and their relationship with prognosis. We analyzed
the clinical data of 139 BIDC cases retrospectively, detecting
EGFR, CD44, and CD24 expressions in tumor tissue using
immunohistochemistry. The proportion of EGFR-, CD44-,
and CD24-positive cases was 59.0, 62.3, and 30.9 %,
respectively. The proportion of CD44-positive [76.9 %
(p \ 0.05)] and EGFR-positive [67.2 % (p = 0.108)] cases
in the triple-negative breast cancer (TNBC) group was
higher than that of the non-TNBC group. In the non-TNBC
group, 36.5 % was CD24-positive, higher than that in the
TNBC group but not statistically significant. The proportion
of CD44-positive cases was significantly higher in the
EGFR-positive group than in the EGFR-negative group
(p = 0.017). EGFR-positive cases were significantly corre-
lated with premenopausal status (p = 0.036), distant
metastasis (p = 0.018), and estrogen receptor-negative sta-
tus (p = 0.020). CD44-positive status was significantly
correlated with human epidermal growth receptor 2 (HER2)-
negative (p = 0.023), estrogen receptor-negative (p =
0.021), and progesterone receptor-negative status (p =
0.004). CD24-positive status was significantly correlated
with HER2-positive status (p = 0.001). Kaplan–Meier sur-
vival analysis showed that TNBC patients had shorter sur-
vival. EGFR-positive and CD44-positive status were both
correlated with shorter survival in the lymph node- and HR-
negative groups, while CD24 positive was significantly
correlated with poor survival in lymph node-negative and
HR-positive patients. EGFR and CD44 expressions have a
significantly positive correlation (p = 0.017) in BIDC.
Patients both EGFR and CD44 positive had the worst
outcome.
Keywords Breast infiltrating ductal carcinoma  EGFR 
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Introduction
Breast cancer is a heterogeneous disease with different
molecular profiles, clinical behaviors, and responses to
therapy. Modern genomic and immunohistochemical
techniques have enabled the classification of breast cancers
into distinct subsets, including hormone receptor positive
(luminal A and luminal B), human epidermal growth
receptor 2 (HER2)-positive, and basal-like type [1]. Triple-
negative breast cancer (TNBC) accounts for 90 % of the
basal-like type and is characterized by its biological
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aggressiveness, worse prognosis, and lack of therapeutic
target in contrast with hormone receptor-positive and
HER2-positive breast cancer [2, 3]. Immunohistochemi-
cally, TNBC is typically negative for estrogen receptor
(ER), progesterone receptor (PR), and HER2, but positive
for basal cytokeratins (CK5/6/14/17), epidermal growth
factor receptor (EGFR), and/or c-kit [4, 5].
EGFR is a cell surface receptor, and its expression has
been implicated in multiple biological processes, including
proliferation, apoptosis, invasion, and angiogenesis, which
are the hallmarks of cancer [6]. Using gene and protein
expressions, previous studies have reported high EGFR
expression in most TNBC [7, 8]. High expression of EGFR
is reported to be associated with poor clinical outcome in
breast cancer, while its prognostic value remains debated
[9, 10].
The stem cell-like phenotype of tumor-initiating cells
and their limited number within the bulk of a tumor may
account for their ability to escape conventional therapies,
leading to disease relapse although the primary lesion has
been removed [11]. In breast cancer, Al-Hajj et al. [12]
were the first to isolate a highly tumorigenic subpopulation
of tumor cells with the CD44?/CD24- phenotype. They
demonstrated that CD44?/CD24- tumor cells resembled
normal stem/progenitor cells with respect to their ability to
self-renew, proliferate, and differentiate [11]. Although
only one-third of human breast cancers have the CD44?/
CD24- phenotype, this tumor cell population appears most
commonly in TNBC [13].
Research on the correlation between EGFR expression
and CD44/CD24 and their prognostic value in breast
invasive ductal carcinoma (BIDC) is limited. In this study,
we aimed to evaluate the correlation between EGFR
expression and CD44/CD24 and determine their relation-
ship with BIDC clinicopathological parameters and their
prognostic value in BIDC.
Materials and methods
Patients and samples
We enrolled 765 patients who had undergone surgery for
primary breast cancer at the First Affiliated Hospital of Sun
Yat-Sen University from January 2000 to December 2005.
Of these, 65 (8.5 %) had TNBC. We selected another 74
luminal or HER2-positive patients (non-TNBC) randomly
as the control. All patients were diagnosed as BIDC by
immunohistochemistry (IHC). All patients underwent rad-
ical mastectomy, modified radical mastectomy, breast-
conserving surgery, or mastectomy. None had received
chemotherapy or radiotherapy before surgery. Adjuvant
systematic therapy (chemotherapy, radiotherapy, endocrine
therapy) was administered as clinically indicated in
accordance with standard practices during this interval.
Clinicopathological information was obtained by reviewing
medical records and pathology reports. We obtained the
following variables: age; tumor size; Bloom-Richardson
histological grade; lymph node status; and ER, PR, and
HER2 status. The Ethics Committee of the First Affiliated
Hospital of Sun Yat-Sen University reviewed and approved
this study, which was performed in accordance with the
ethical standards described in the Declaration of Helsinki.
Overall follow-up was calculated from the date of surgery
to the date of the last follow-up (April 2013) or breast
cancer-related death. The median follow-up period was
97 months (2–156 months).
Immunohistochemistry
Paraffin-embedded primary tumor tissue was retrieved
from the First Affiliated Hospital of Sun Yat-Sen Univer-
sity Department of Pathology, from which we obtained
4-lm-thick sections. We used the DAKO EnVision system
(DAKO EnVision labeled polymer, peroxidase; Dako,
Glostrup, Denmark) to detect CD44 (1:200; ZSGB-bio,
Beijing, China), CD24 (1:200; ZSGB-bio), and EGFR
(1:200; ZSGB-bio). The appropriate positive controls were
Table 1 Patient characteristics
Parameters Patients, n (%)
TNBC
(n = 65) (%)
Non-TNBC
(n = 74) (%)
Age group
\35years 7 (10.8) 9 (12.2)
C35years 58 (89.2) 65 (87.8)
Tumor size
\3cm 30 (46.2) 44 (59.5)
C3cm 35 (53.8) 30 (40.5)
Lymph node
Positive 33 (50.8) 28 (37.8)
Negative 32 (49.2) 46 (62.2)
Menopausal
Premenopausal 31 (47.7) 35 (47.3)
Postmenopausal 34 (52.3) 39 (52.7)
Pathological stage
III 37 (56.9) 20(27.0)
I–II 28(43.1) 54(73.0)
Surgery
Radical mastectomy 35 (53.8) 8 (10.8)
Modified radical mastectomy 22 (33.8) 62 (83.8)
Mastectomy 3 (4.6) 2(2.7)
Breast-conserving 5 (5.8) 2 (2.7)
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used. Phosphate-buffered saline was substituted for the
primary antibody as the negative control. The color was
developed through incubation with 3, 30-diaminobenzidine.
Two pathologists scored the proportion of positively
stained tumor cells and staining intensity independently,
and a consensus score was given for each case. CD44 and
CD24 staining was detected mainly in the cell membrane
and occasionally in the cytoplasm. According to Wu et al.
[14], the intensity of positive staining was scored as fol-
lows: (???) for high-intensity staining, (??) for mod-
erate staining, (?) for low intensity, and (-) for no
staining. The percentage of stained cells was categorized as
0 (negative), 1 (\10 % positive cells), 2 (11–50 % positive
cells), 3 (51–80 % positive cells), and 4 (80–100 % posi-
tive cells). The final quantification of IHC results for both
variables (staining intensity and percentage of positively
stained cells) was considered (score = staining inten-
sity 9 positive staining).
EGFR staining was detected mainly in the cell mem-
brane and cytoplasm. The proportion of positively stained
cells was scored as follows: 0 (no positive cells), 1 (\25 %
positive cells), 2 (26–50 % positive cells), 3 (50–75 %
positive cells), and 4 ([75 % positive cells). Staining
intensity was graded as follows: 0 (no staining), 1 (weak
staining = light yellow), 2 (moderate staining = yellow
brown), and 3 (strong staining = brown). The staining
index was calculated as the product of the staining intensity
score and proportion of positive cells. A staining index
score of B6 indicated negative expression; a staining index
score of [6 indicated positive expression.
Statistical analyses
Disease-free survival (DFS) was defined as the duration
from the date of primary surgery to the first local recur-
rence or distant metastasis. Overall survival (OS) was the
duration from the date of primary surgery to the time of
breast cancer-related death or the last follow-up.
Statistical analysis was performed using SPSS 17.0 sta-
tistical software (SPSS Inc., Chicago, IL, USA). The Chi-
square test was used to analyze the relationship between
Fig. 1 a Positive staining of EGFR in the cell membrane and cytoplasm. b, c CD44 and CD24 expression in breast cancer cells in the membrane
and occasionally in the cytoplasm(x400)











Positive 82 (59.0) 43 (66.2) 39 (52.7) 2.588 0.108
Negative 57 (41.0) 22 (33.8) 35 (47.3)
CD44
Positive 87 (62.6) 50(76.9) 37(50) 10.712 0.001*
Negative 52 (37.4) 15(23.1) 37(50)
CD24
Positive 43 (30.9) 16(24.6) 27(36.5) 2.282 0.131
Negative 96 (69.1) 49(75.4) 47(63.5)
CD44?/CD24-
Yes 61(43.9) 36(55.4) 25(33.7) 6.557 0.010*
No 78(56.1) 29(44.6) 49(66.3)
* p \ 0.05
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EGFR, CD44/CD24 expressions, and clinicopathological
variables. The association with survival was analyzed using
the Kaplan–Meier plot and log-rank test. Survival data were
evaluated using univariate and multivariate Cox regression
analyses to adjust for other prognostic indicators. A p value
of 0.05 was considered statistically significant.
Results
Tumor clinicopathological features
In total, we included 139 BIDC patients (TNBC, 65 cases;
non-TNBC, 74 cases) in this study and analyzed their
EGFR, CD44, and CD24 expressions. Table 1 summarizes
the patient and tumor characteristics. All patients were all
female; the median age was 50 years (range, 28–82 years).
EGFR, CD44, and CD24 expressions
Positive IHC staining of EGFR was detected in the cell
membrane and cytoplasm in 82 cases (59.0 %; Fig. 1a).








Positive 58 (70.7) 28 (49.1) 0.017*
Negative 24 (29.3) 29 (50.9)
CD24
Positive 25 (30.5) 18 (31.6) 0.891
Negative 57 (69.5) 39 (68.4)
CD44?/CD24-
Yes 42 (51.2) 19 (33.3) 0.037*
No 40 (48.8) 38 (66.7)
* p \ 0.05
Table 4 Correlation between
marker expression and
clinicopathological parameters
* p \ 0.05
Parameters EGFR p value CD44 p value CD24 p value
- ? - ? - ?
Tumor grade 0.116 0.392 0.295
G1 4 16 7 13 16 4
G2 27 35 27 35 39 23
G3 26 31 18 39 41 16
Age 0.166 0.994 0.585
\35 years 4 12 6 10 12 4
C35 years 53 70 46 77 84 39
Menopausal status 0.036* 0.345 0.374
Premenopausal 21 45 22 44 48 18
Postmenopausal 36 37 30 43 48 25
Distant metastasis 0.018* 0.064 0.249
Yes 44 46 37 53 64 26
No 11 30 10 31 25 16
Censored 2 6 5 3 7 1
Lymph node metastasis 0.724 0.261 0.489
Negative 33 45 26 52 52 26
Positive 24 37 26 35 44 17
Tumor size 0.567 0.554 0.487
\3cm 32 42 26 48 53 21
C3cm 25 40 26 39 43 22
HER2 status 0.768 0.023* 0.001*
Negative 45 63 35 73 82 27
Positive 12 19 17 14 14 16
ER status
Negative 30 59 0.020* 27 62 0.021* 63 26 0.558
Positive 27 23 25 25 33 17
PR status
Negative 28 50 0.166 21 57 0.004* 55 23 0.676
Positive 29 32 31 30 41 20
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Positive CD44 and CD24 expressions were detected in the
cell membrane and occasionally in the cytoplasm (Fig. 1b,
c). There were positive CD44 and CD24 expressions in
87/139 (62.6 %) and 43/139 cases (30.9 %), respectively.
Table 2 details the EGFR, CD44, and CD24 expressions in
the TNBC and non-TNBC cases. More EGFR-positive
patients were also CD44-positive and CD44?/CD24-
subtypes compared to EGFR-negative patients (p = 0.017
and p = 0.037, respectively; Table 3); CD24 expression
between the two groups was not statistically significant
(p = 0.89). EGFR expression was associated with meno-
pausal (p = 0.036) and ER-positive status (p = 0.020),
CD44 expression was associated with HER2-positive
(p = 0.023), ER-positive (p = 0.021) and PR-positive
status (p = 0.004), and CD24 expression was associated
with HER2-positive status (p = 0.001). Patients who were
EGFR and CD44 positive were more likely to develop
distant metastases (p = 0.018 and p = 0.064, respectively;
Table 4).
Survival analysis
Univariate analysis showed that TNBC patients had sig-
nificantly worse DFS (p \ 0.001) and OS (p = 0.001) than
non-TNBC patients. The same was observed in patients
who were EGFR positive (DFS: p = 0.002, OS:
p = 0.003) and CD44 positive (DFS: p = 0.007, OS:
p = 0.034). However, there was no significant difference
between DFS and OS in CD24-positive and CD24-negative
patients. Multivariate analysis for all patients indicated that
TNBC and positive EGFR staining were significant prog-
nostic factors for DFS and OS. (Table 5).
Figure 2 depicts the survival curves. In stratified ana-
lysis, in node-negative patients and EGFR-positive
patients, DFS and OS were significantly shorter than those
in EGFR-negative patients (p = 0.019 and p = 0.006);
CD44 and CD24 positive both showed an inferior OS
(p \ 0.05, Fig. 3). In node-positive patients, EGFR, CD44,
and CD24 expressions did not show a significant
Table 5 Multivariate analysis
* p \ 0.05
Parameters DFS OS
Hazard ratio p value 95 % CI Hazard ratio p value 95 % CI
Tumor size (C3cm) 1.566 0.153 0.846–2.897 1.830 0.071 0.950–3.526
Lymph node metastases 1.703 0.090 0.920–3.152 1.548 0.177 0.820–2.921
EGFR positive 2.255 0.023* 1.116–4.555 2.449 0.016* 1.180–5.080
CD44 positive 1.555 0.225 0.762–3.173 1.929 0.109 0.864–4.308
TNBC 2.088 0.023* 1.105–3.946 2.198 0.021* 1.124–4.295
Fig. 2 a, e TNBC-, b, f EGFR-, and c, g CD44-positive patients had significantly worse DFS and OS. d, h There was no significant difference in
DFS and OS between CD24-positive and CD24-negative patients
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relationship with the DFS and OS, (Fig. 4). In HR (hor-
mone receptor)-negative patients, EGFR-- and CD44--
positive patients both experienced shorter DFS (p = 0.044,
p = 0.063) and OS (p = 0.016, p = 0.038; Fig. 5). In HR-
positive subtype, CD24-positive patients had significantly
worse DFS (p \ 0.05, Fig. 6). In EGFR-/CD44-stratified
analysis, patients with EGFR?/CD44? subtype had the
worst prognosis, patients with EGFR/CD44 single positive
subtype followed, patients with EGFR-/CD44- subtype
had the best prognosis (Fig. 7).
Discussion
IDC is the most common type of breast cancer. BIDC can
be divided into triple-negative and non-triple-negative
based on the hormone receptor status. TNBC accounts for
10–17 % of all breast cancers [15]. As we studied IDC in
the present study, TNBC only accounted for 8.5 % of all
breast cancers.
TNBC is relatively large, high grade, has a high rate of
node positivity at diagnosis, and is biologically more
aggressive. Despite the higher rates of clinical response to
neoadjuvant chemotherapy, TNBC patients have a higher
rate of distant recurrence and poorer prognosis compared
with patients with other breast cancer subtypes [2, 3].
Consistent with the literature, our findings demonstrated
that TNBC patients had significantly worse DFS and OS
compared with non-TNBC patients (Fig. 2a, e).
EGFR is expressed in all types of breast cancer, espe-
cially in TNBC [5, 16]. EGFR was first reported as a sig-
nificant prognostic factor in breast cancer by Sainsbury
Fig. 3 In node-negative
patients, EGFR-positive patients
DFS and OS were significantly
lower than EGFR-negative
patients (a, b) ; CD44- and
CD24-positive both showed a
significant negative correlation
with OS (c, e)
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et al. [17]. Since then, many researchers have reported
differing findings on the prognostic value of EGFR in
breast cancer, and there is still no agreement on the rela-
tionship between EGFR and clinical outcome [18, 19]. In
the present study, EGFR expression was inversely corre-
lated with ER status (p = 0.023). Although EGFR was
frequently expressed in TNBC, there was no statistically
significant difference between TNBC and non-TNBC
patients (p = 0.108). EGFR-positive patients were more
likely to develop distant metastases (p = 0.018), which
indicated that EGFR may be an important prognostic factor
for distant metastasis. Survival analysis showed that EGFR
positive indicated significantly shorter survival time in the
lymph node- and HR-negative group. These data strongly
indicate that EGFR-positive status is related to breast
cancer progression and is a pivotal prognostic factor for
specific subgroup.
Although EGFR-positive status is correlated with poor
clinical prognosis, Tang et al. [20] found that EGFR
overexpression predicted better response to neoadjuvant
chemotherapy in patients with TNBC. This is a possible
reason that TNBC is more chemosensitive.
Numerous studies have reported that CD44?/CD24-
epithelial tumor cells are the most common in TNBC [14,
21, 22], but the relationship between CD44?/CD24- cells
and prognosis in breast cancer is debated. Lee et al.
reported that a high proportion of CD44?/CD24- tumor
cells in prechemotherapy tissue was correlated with higher
Fig. 4 In node-positive
patients, EGFR (a, b), CD44 (c,
d) and CD24 (e, f) did not show
a significant relationship with
the OS and DFS
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histological grade, ER negativity, and high Ki-67 prolif-
eration index. After primary systemic therapy, the pro-
portions of CD44?/CD24- tumor cells were significantly
increased [23]. Wu et al. [14] demonstrated that the
CD44?/CD24- and CD24?/CD44- phenotypes associ-
ated with decreased DFS but were not independent pre-
dictors for DFS. Giatromanolaki et al. [22] reported that
the CD44?/CD24- and CD44-/CD24- phenotypes
indicated unfavorable prognosis in TNBC. However, Kim
and colleagues reported that the CD44?/CD24- group is
considered a favorable prognostic subgroup in breast
cancer. CD24 expression was a poor prognostic marker in
HR-positive breast cancer, and CD44 expression was a
good prognostic marker in the HR-negative group [24].
Another study showed that there was no correlation
between the CD44?/CD24- phenotype and outcome in
HR-positive breast cancer [25]. In the present study, 76.9
and 50 % of TNBC and non-TNBC patients, respectively,
showed positive CD44 expression (p \ 0.05). However,
CD24 did not show statistically different expression levels
between the two groups (p = 0.131). CD44-positive
expression was inversely associated with HER2-positive
status and HR-positive status, while CD24-positive
expression was correlated with HER2-positive status but
had nothing to do with HR-positive status. This study
showed that CD44 positive was significantly correlated
with survival time only in lymph node- and HR-negative
patients while CD24 positive was significantly correlated
with survival time in lymph node-negative and HR-posi-
tive patients.
Fig. 5 In HR (hormone
receptor) negative patients,
EGFR-(a, b) and CD44-(c,
d) positive patients both
experienced shorter OS and
DFS
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Although the rate of EGFR expression is high in breast
cancer, especially in TNBC, EGFR inhibitors do not have
an ideal curative effect in breast cancer. Previous studies
have suggested that synthetic lethal cross-linking of
inhibitors of the mitogen-activated protein kinase (MAPK)
kinase (MEK)/MAPK pathway, EGFR, and poly(ADP-
ribosyl) transferase (PARP) may be related [26, 27]. In this
study, EGFR and CD44 expressions were significantly
positively correlated (p = 0.017). The CD44?/CD24-
tumor cell phenotype is recognized as a cancer stem cell
characteristic [11]. It is believed that CD44?/CD24-
breast cancer cells are highly invasive and radioresistant
and chemoresistant [28]. The close correlation between
CD44 and EGFR expressions may be another reason for the
resistance to EGFR inhibitors in breast cancer. Combining
EGFR inhibitors with CD44 inhibitors may be a novel
method for breast cancer treatment, especially TNBC.
In conclusion, our study indicates that in combination,
EGFR and CD44/CD24 expression status are powerful
identifiers of breast cancer patient subgroups with dif-
ferent clinical behavior. Although our study has some
limitations, such as its retrospective design and relatively
small number of studied patients, the data obtained
indicate that EGFR and CD44 could serve as useful
biomarkers for better determination of the prognosis of
invasive breast cancer. These findings may have thera-
peutic significance and may improve the management of
breast cancer patients.
Fig. 6 In HR-positive subtype,
CD24-positive patients had
significantly worse DFS (f)
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